Court Opinion

ID: 4301494
Source: CourtListenerOpinion
Date Created: 2018-08-07 13:13:27.586493+00
Date Added: 2024-06-11T07:49:32.151746
License: Public Domain

IN THE COMMONWEALTH COURT OF PENNSYLVANIA

Armour Pharmacy,                                :
                        Petitioner              :
                                                :
                 v.                             : No. 1613 C.D. 2017
                                                : Argued: June 4, 2018
Bureau of Workers’ Compensation                 :
Fee Review Hearing Office (National             :
Fire Insurance Company of Hartford),            :
                  Respondent                    :

BEFORE:          HONORABLE MARY HANNAH LEAVITT, President Judge
                 HONORABLE PATRICIA A. McCULLOUGH, Judge
                 HONORABLE CHRISTINE FIZZANO CANNON, Judge

OPINION
BY PRESIDENT JUDGE LEAVITT                                           FILED: August 7, 2018

                 Armour Pharmacy (Pharmacy) petitions for review of an adjudication
of the Bureau of Workers’ Compensation, Fee Review Hearing Office (Hearing
Office) that vacated a fee review determination by the Bureau’s Medical Fee Review
Section that Pharmacy was entitled to be paid $6,644.30, plus interest, for
medication it had dispensed to Mark Kraayenbrink (Claimant). The Hearing Office
did so because Claimant had released his employer from liability for this particular
treatment in a Compromise and Release (C&R) Agreement that was approved by a
Workers’ Compensation Judge (WCJ). Notably, this C&R Agreement was executed
after the fee review determination was issued and while the employer’s challenge
thereto was pending. Pharmacy argues that the C&R Agreement cannot be used to
set aside a fee review determination; rather, a fee review determination in favor of a
provider may be set aside only by following the fee review procedures set forth in
the Workers’ Compensation Act1 (Act). Pharmacy also argues that the C&R

1
    Act of June 2, 1915, P.L. 736, as amended, 77 P.S. §§1-1041.4, 2501-2708.
Agreement, to which it was not a party, deprived it of its property rights in violation
of the Act and in violation of Pharmacy’s constitutional guarantee of due process of
law. We vacate and remand.
                                        Background
              In 1999, Claimant sustained a back injury while working for Cabinet
Transport, Inc. (Employer). In 2000, Claimant and Employer entered into a C&R
Agreement that settled Claimant’s disability compensation but left Employer
responsible for Claimant’s medical treatment. Since 2000, Employer has covered
Claimant’s medical treatment.2
              In 2015, Employer requested a utilization review of a topical compound
cream prescribed by Jason Bundy, M.D. to treat Claimant’s work injury, i.e.,
neuropathy. This compounded cream consisted of “ketamine 10%, flurbiprofen
10%, gabapentin 10%, cyclobenzaprine 3%, bupivacaine 2% within a transdermal
base” and was to be applied as needed. Utilization Review Determination at 5;
Reproduced Record at 7a (R.R. __). On September 9, 2015, the utilization review
organization determined that the compound cream prescribed by Dr. Bundy to
Claimant was reasonable and necessary to treat Claimant’s accepted work injury.
Employer did not appeal.
              In early 2016, Dr. Bundy prescribed the identical compound cream to
Claimant. Pharmacy dispensed the cream and billed Employer on April 19, 2016,
but Employer refused to pay Pharmacy’s invoice, “based on utilization review.”
R.R. 14a.      Pharmacy filed a timely fee review application with supporting
documents. On July 25, 2016, the Medical Fee Review Section of the Bureau

2
 The insurer responsible for Claimant’s workers’ compensation benefits is National Fire Insurance
Company of Hartford.
                                               2
determined that Employer owed Pharmacy $6,644.30, plus ten percent interest to be
calculated as of the 30th day after Pharmacy had submitted its invoice for payment.
On August 5, 2016, Employer requested a hearing to contest the fee review
determination on the following grounds:

               Claimant has been prescribed compound medications which are
               overly inflated in price, with self-interest from the prescriber, are
               not FDA approved and generally contain the same medications
               that can be taken orally at a significant price reduction. The
               medicine is not reasonable nor medically necessary.

R.R. 32a. The hearing requested by Employer was convened on November 18, 2016,
before a hearing officer appointed by the Hearing Office.
               At the hearing’s inception, Employer alleged that Dr. Bundy had a
financial interest in Pharmacy and, thus, his prescription constituted an unlawful
“self-referral.” Notes of Testimony at 6 (N.T. ___); R.R. 86a. Noting that the
question of whether the provider self-referral prohibition in the Act3 applies to
pharmacies was pending in several cases, the Hearing Officer stated that he would

3
 Section 306(f.1)(3)(iii) of the Act provides:
        Notwithstanding any other provision of law, it is unlawful for a provider to refer a
        person for laboratory, physical therapy, rehabilitation, chiropractic, radiation
        oncology, psychometric, home infusion therapy or diagnostic imaging, goods or
        services pursuant to this section if the provider has a financial interest with the
        person or in the entity that receives the referral. It is unlawful for a provider to
        enter into an arrangement or scheme such as a cross-referral arrangement, which
        the provider knows or should know has a principal purpose of assuring referrals by
        the provider to a particular entity which, if the provider directly made referrals to
        such entity, would be in violation of this section. No claim for payment shall be
        presented by an entity to any individual, third-party payer or other entity for a
        service furnished pursuant to a referral prohibited under this section.
77 P.S. §531(3)(iii) (emphasis added).
                                                 3
defer ruling on that question. Accordingly, the Hearing Officer instructed Employer
to “move on” to the “non-self-referral issues.” N.T. at 8; R.R. 88a.
              Employer then presented a copy of a C&R Agreement, which was
approved by a WCJ on October 28, 2016 (2016 C&R Agreement), three months after
the Medical Fee Review Section directed Employer to pay Pharmacy $6,644.30 plus
interest.4 The 2016 C&R Agreement states, in relevant part, as follows:

              Upon approval of this Agreement Defendant/ Employer shall pay
              reasonable, necessary and related medical expenses incurred
              before the hearing date. No past, present or future benefits shall
              be paid for any compounded prescription cream, including but
              not limited to compound prescription creams prescribed by
              physician Dr. Jason Bundy. (see Addendum)

2016 C&R Agreement, ¶10; R.R. 59a (emphasis added).                     The corresponding
Addendum stated:

              After an investigation, Defendants have reason to believe that Dr.
              Bundy has a financial interest in [Pharmacy] in violation of
              [S]ection 306(f.1)(3)(iii) of the Act[, 77 P.S. §531(3)(iii)] and
              Sections 127.301 and 127.302 of the Medical Cost Containment
              Regulations[, 34 Pa. Code §§ 127.301-127.302]. Consistent with
              Section 306(f.1)(7) [of the Act, 77 P.S. §531(7)] neither provider
              Dr. Bundy nor [Pharmacy] shall hold the Claimant responsible
              for any charges related to the above mentioned compounding
              prescription cream.

Addendum to ¶10, R.R. 62a. Employer asserted that paragraph 10 of the 2016 C&R
Agreement relieved it of liability to pay Pharmacy’s invoice for the compound
creams and, thus, the Hearing Officer lacked jurisdiction to proceed further on

4
  Specifically, the Medical Fee Review Section ordered Employer to pay Pharmacy on July 25,
2016. On September 15, 2016, Employer petitioned for approval of the C&R Agreement. It was
approved by the WCJ on October 28, 2016, shortly before the hearing on Employer’s challenge to
the fee review determination.
                                              4
Employer’s request for a hearing to contest the fee review determination in favor of
Pharmacy.
             Pharmacy replied that it was not a party to the 2016 C&R Agreement,
which was executed long after Pharmacy had dispensed the medication and the
Medical Fee Review Section had made its determination that Employer was liable
for the cost plus interest. Pharmacy contended that a C&R Agreement could not be
used “to invalidate or subvert a legal process” established in the Act for a review of
a provider’s fees. N.T. at 13-14; R.R. 93a-94a. Pharmacy further contended that its
vested right to the payment ordered by the Medical Fee Review Section could not
be “extinguished” without notice and an opportunity to be heard. Id.
             At the direction of the Hearing Officer, the parties submitted briefs on
the threshold question of whether the 2016 C&R Agreement deprived the Hearing
Officer of jurisdiction over Employer’s challenge to the fee review determination.
On October 3, 2017, the Hearing Officer issued the instant adjudication. He
concluded that in light of the 2016 C&R Agreement, which extinguished Employer’s
past, present and future liability for compound creams, the Medical Fee Review
Section’s “Administrative Determination cannot stand.”              Hearing Office
Adjudication at 6. In response to Pharmacy’s due process arguments, the Hearing
Officer explained that he lacked the authority to address constitutional questions.
Likewise, he lacked jurisdiction to consider the merits of the 2016 C&R Agreement,
which was a matter committed solely to the discretion of the WCJ. Accordingly, the
Hearing Officer granted Employer’s motion to dismiss and vacated the July 25,
2016, fee review determination that Employer owed Pharmacy $6,644.30, plus

                                          5
interest, for the compound cream prescribed to Claimant. Pharmacy then petitioned
for this Court’s review of the Hearing Office’s adjudication.5
              On appeal, Pharmacy challenges the Hearing Office’s adjudication as
violative of Pharmacy’s right to payment under the Act for medications it dispensed
for treatment of Claimant’s accepted work injury. Pharmacy contends that the
Hearing Office erred in relying upon the C&R Agreement, which was employed
improperly to deprive Pharmacy of due process of law and to usurp the procedures
in the Act for resolving fee disputes. Finally, Pharmacy argues that Employer
waived its ability to use the 2016 C&R Agreement as the basis of its motion to
dismiss.6
                                      Applicable Law
              The Act requires employers to make prompt payment on provider
invoices for reasonable and necessary medical treatment of a claimant’s work injury.
The Act also establishes specific procedures for resolving disputes between a
provider and an employer about whether the treatment that generated the invoice
actually meets that standard. Section 301(f.1)(5) states:

              The employer or insurer shall make payment and providers shall
              submit bills and records in accordance with the provisions of this
              section. All payments to providers for treatment provided

5
  Our review in medical fee review cases determines whether constitutional rights were violated,
whether an error of law was committed, or whether the necessary findings of fact were supported
by substantial evidence. Pittsburgh Mercy Health System v. Bureau of Workers’ Compensation,
Fee Review Hearing Office (U.S. Steel Corp.), 980 A.2d 181, 184 n.4 (Pa. Cmwlth. 2009).
Regarding questions of law, our scope of review is plenary and our standard of review is de novo.
Sedgwick Claims Management Services, Inc., v. Bureau of Workers’ Compensation, Fee Review
Hearing Office (Piszel and Bucks County Pain Center), 185 A.3d 429, 433 n.2 (Pa. Cmwlth. 2018).
6
  Pharmacy asserts waiver because Employer’s request for a hearing to contest the fee review
determination did not cite the 2016 C&R Agreement. It did not yet exist. Because we decide the
appeal on other grounds, we do not address Pharmacy’s waiver claim.
                                               6
             pursuant to this act shall be made within thirty (30) days of
             receipt of such bills and records unless the employer or insurer
             disputes the reasonableness or necessity of the treatment
             provided pursuant to paragraph (6). The nonpayment to
             providers within thirty (30) days for treatment for which a bill
             and records have been submitted shall only apply to that
             particular treatment or portion thereof in dispute; payment must
             be made timely for any treatment or portion thereof not in
             dispute. A provider who has submitted the reports and bills
             required by this section and who disputes the amount or
             timeliness of the payment from the employer or insurer shall file
             an application for fee review with the department no more than
             thirty (30) days following notification of a disputed treatment or
             ninety (90) days following the original billing date of treatment.
             If the insurer disputes the reasonableness and necessity of the
             treatment pursuant to paragraph (6), the period for filing an
             application for fee review shall be tolled as long as the insurer
             has the right to suspend payment to the provider pursuant to the
             provisions of this paragraph. Within thirty (30) days of the filing
             of such an application, the department shall render an
             administrative decision.

77 P.S. §531(5) (emphasis added). “Paragraph 6” states, in relevant part, as follows:

             [D]isputes as to reasonableness or necessity of treatment by a
             health care provider shall be resolved in accordance with the
             following provisions:
                   (i)    The reasonableness or necessity of all
                   treatment provided by a health care provider under
                   this act may be subject to prospective, concurrent or
                   retrospective utilization review at the request of an
                   employe, employer or insurer. The department
                   shall authorize utilization review organizations to
                   perform utilization review under this act.
                   Utilization review of all treatment rendered by a
                   health care provider shall be performed by a
                   provider licensed in the same profession and having
                   the same or similar specialty as that of the provider
                   of the treatment under review.

                                          7
77 P.S. §531(6) (emphasis added).
            In sum, where an employer challenges a provider’s treatment as neither
reasonable nor necessary, it must seek utilization review pursuant to Section
301(f.1)(6) of the Act. Until the utilization review determination is issued, the
employer may “suspend payment to the provider.” Section 301(f.1)(5), 77 P.S.
§531(5). Where a provider does not receive payment within 30 days (and payment
has not been stayed by an employer’s utilization review request), it has recourse.
The provider may file a fee review petition under Section 301(f.1)(5) of the Act,
which gives that provider a right to prompt payment for reasonable and necessary
medical treatment of a claimant’s accepted work injury.
            Notably, a fee review proceeding cannot be used to establish that a
claimant has a work-related injury for which the employer has liability. As this
Court has explained:

            the fee review process presupposes that liability has been
            established, either by voluntary acceptance by the employer or a
            determination by a WCJ. Neither the Act nor the medical cost
            containment regulations provide any authority for a fee review
            officer to decide the issue of liability in a fee review proceeding.
            The Department’s regulations, at 34 Pa.Code § 127.255(1), state
            that an application for fee review filed by a provider is premature
            and will be returned if “[t]he insurer denies liability for the
            alleged work injury.” The issue for the fee review officer is the
            “amount and timeliness of the payment made by an insurer.” 34
            Pa.Code § 127.251.

Nickel v. Workers’ Compensation Appeal Board (Agway Agronomy), 959 A.2d 498,
503 (Pa. Cmwlth. 2008) (emphasis added). Any dispute about whether a claimant
has a work injury, or the scope of that injury, must be litigated in accordance with
the procedures of the Act for a claim petition proceeding. See Inglis House v.

                                         8
Workmen’s Compensation Appeal Board (Reedy), 634 A.2d 592, 595 (Pa. 1993)
(“[I]n a claim proceeding, the employee bears the burden of establishing a right to
compensation and of proving all necessary elements to support an award”).
                Pharmacy argues it has a right to payment under Section 301(f.1)(5) of
the Act, which is a right protected by due process of law.7 It contends that
Employer’s collusive 2016 C&R Agreement was designed solely to nullify the
Medical Fee Review Section’s determination and to bypass the fee review
procedures set forth in Section 301(f.1)(5) of the Act. Employer responds that
Section 449(a) of the Act8 provides that “[n]othing in this act shall impair the right
of the parties interested to compromise and release, subject to the provisions herein
contained, any and all liability which is claimed to exist under this act on account of
injury or death.” 77 P.S. §1000.5(a). Employer maintains that the 2016 C&R
Agreement was consistent with Section 449(a) of the Act and relieved it of liability
to pay Pharmacy’s invoice as directed by the Medical Fee Review Section.
                The central question in this appeal is whether a C&R agreement can be
used to set aside a fee review determination that an employer owes reimbursement
to a provider for a particular course of treatment.

7
    The Due Process Clause of the Fourteenth Amendment states as follows:
      No State shall make or enforce any law which shall abridge the privileges or
      immunities of citizens of the United States; nor shall any State deprive any person
      of life, liberty, or property, without due process of law; nor deny to any person
      within its jurisdiction the equal protection of the laws.
U.S. CONST. amend. XIV, §1. The Pennsylvania Constitution also provides this protection. PA.
CONST. art. I, §9.
8
  Added by the Act of June 24, P.L. 350, 77 P.S. §1000.5(a).
                                                9
                                      Analysis
              On May 10, 2016, Employer denied payment of Pharmacy’s April 19,
2016, bill in its entirety “based on utilization review.” R.R. 14a. As noted by the
Hearing Officer, Employer “attacked” the 2015 utilization review determination that
the compound cream was medically necessary, but it did not appeal that
determination in accordance with the provisions of the Act.            Hearing Office
Adjudication at 4, n.3. Nor did Employer seek a utilization review of the 2016
prescription that was dispensed by Pharmacy or allege that Claimant’s condition
changed since 2015. Id. at 3, n.2. Employer’s refusal to pay Pharmacy’s 2016
invoice violated the Act and the Department’s implementing regulation.
              First, if Employer wanted to suspend its obligation to pay Pharmacy’s
2016 invoice within 30 days, it had to file a new utilization review application in
accordance with Section 301(f.1)(6) of the Act. It did not do so and, thus, it lacked
a lawful basis not to pay Pharmacy promptly in accordance with Section 301(f.1)(5)
of the Act.
              Second, the Department’s regulation provides that where a “bill is
denied entirely, insurers shall provide a written explanation of the denial.” 34 Pa.
Code §127.209. Employer gave a false reason, i.e., that Pharmacy’s invoice was
denied on the basis of “utilization review.”       This was contrary to the 2015
determination of the utilization review organization that the compound cream was
reasonable and necessary to treat Claimant’s neuropathy. Giving a false reason, even
one in writing, is not the “explanation” required by the regulation.
              Pharmacy properly responded to Employer’s refusal to pay by
submitting a timely application for fee review under Section 306(f.1)(5) of the Act.
The Medical Fee Review Section promptly granted Pharmacy’s application,

                                         10
calculating the amount owed to be $6,644.30 and 10% interest on the unpaid sum
“calculated from the date payment on each bill was due.” R.R. 25a.
               Employer relies upon paragraph 10 of the 2016 C&R Agreement that
purported to dissolve Employer’s liability for any past, present and future compound
creams. However, paragraph 10 also states that Employer “shall pay reasonable,
necessary and related medical expenses incurred before the hearing date [on the 2016
C&R Agreement].” R.R. 59a (emphasis added). This includes the compound cream
issued to Claimant in 2016, which was specifically determined by the Medical Fee
Review Section to be reasonable and necessary in 2015 before the hearing on the
2016 C&R Agreement. In short, paragraph 10 obligated Employer to pay for the
“reasonable and necessary” compound creams dispensed by Pharmacy in 2016
because the expense therefor had already been “incurred.”9 Id.
               A valid C&R agreement is “binding upon the parties.” Department of
Labor & Industry, Bureau of Workers’ Compensation v. Workers’ Compensation
Appeal Board (US Food Service), 932 A.2d 309, 314 (Pa. Cmwlth. 2007). However,
Pharmacy was not a party to the 2016 C&R Agreement. Accordingly, Employer’s
reliance upon Section 449(a) of the Act is misplaced. The scope of Section 449(a)
is limited to “parties interested” that wish to “compromise and release … any and
all liability” under the Act. 77 P.S. §1000.5(a). This does not include the provider.10

9
  Claimant has no liability to Pharmacy. Section 306(f.1)(7) provides: “[a] provider shall not hold
an employe liable for costs related to care or service rendered in connection with a compensable
injury under this act. A provider shall not bill or otherwise attempt to recover from the employe
the difference between the provider’s charge and the amount paid by the employer or the insurer.”
77 P.S. §531(7).
10
   The other provisions of Section 449 speak to the rights of the “employer or insurer” and “the
claimant” (or his dependents or survivors). 77 P.S. §1000.5.
                                               11
Further, as a matter of due process, Pharmacy cannot be deprived of its rights under
the Act except in accordance with due process of law.
              In In re Upset Sale, 479 A.2d 940 (Pa. 1984), the Pennsylvania
Supreme Court affirmed that the U.S. Constitution requires notice and an
opportunity to be heard before property or property rights may be taken, particularly
when the process is part of a state regulatory scheme. The Court stated:

              The Due Process Clause of the Fourteenth Amendment to the
              Federal Constitution requires at a minimum that the deprivation
              of life, liberty or property by adjudication must be preceded by
              notice and opportunity for hearing appropriate to the nature of
              the case. The United States Supreme Court beginning with
              Mullane v. Central Hanover Bank and Trust Co., 339 U.S. 306,
              94 L. Ed. 865, 70 S. Ct. 652 (1950), has invoked the Due Process
              Clause and required states to make efforts to provide actual
              notice to all parties whose interests are affected by proceedings
              before a tribunal.

Id. at 943.
              In Mullane v. Central Hanover Bank and Trust Co., 339 U.S. 306
(1950), the U.S. Supreme Court explained that:

              An elementary and fundamental requirement of due process in
              any proceeding which is to be accorded finality is notice
              reasonably calculated, under all the circumstances, to apprise
              interested parties of the pendency of the action and afford them
              an opportunity to present their objections.

The Court further held that the “notice must be of such nature as reasonably to
convey the required information, and it must afford a reasonable time for those
interested to make their appearance.” Id. (internal citations omitted).
              In Baksalary v. Smith, 579 F. Supp. 218 (E.D. Pa. 1984), the U.S.
District Court held that the “automatic supersedeas” provision of the Act, which

                                         12
allowed an employer to suspend a claimant’s disability compensation without a prior
hearing, was unconstitutional under the Due Process Clause of the Fourteenth
Amendment. That the claimant could eventually have his compensation reinstated
was not sufficient to satisfy due process because the claimant “had no avenue to
contest [the suspension’s] application.” Id. at 221-22.
             The Act’s utilization review and fee review procedures have been
designed to comport with due process. They give both the employer and provider
an opportunity to be heard on the factual question of whether a provider’s treatment
was reasonable and necessary and, thus, required to be paid for by the employer. A
C&R agreement, to which a provider is not a party, cannot be used to deprive a
provider of the review procedures and excuse the employer from paying the
provider. To do so would violate the Act and due process. Baksalary, 579 F. Supp.
at 221-22.
             Also instructive is Gingerich v. Workers’ Compensation Appeal Board
(U.S. Filter), 825 A.2d 788 (Pa. Cmwlth. 2003). In that case, a claimant and her tort
counsel entered into a C&R agreement with the employer that, inter alia, allowed
the claimant to retain the tort claim award and released the employer from future
payment of her compensation counsel’s fees. This Court held that neither the
claimant nor her employer could deprive her compensation counsel of these fees via
a C&R Agreement. Neither was “the person with the claim.” Id. at 791. Likewise,
here, Claimant had no authority to “release” Employer from its liability to Pharmacy
because Claimant was not “the person with the claim.” Nor could Employer release
itself from its liability to Pharmacy established by the Medical Fee Review Section.
The parties to a C&R agreement can bind each other, but they cannot release
themselves from liability to a person who is not a party to the C&R agreement and

                                         13
who has been given neither notice nor opportunity to be heard on the C&R
Agreement.
                                      Conclusion
             The 2016 C&R Agreement holds Employer liable for all “reasonable,
necessary and related medical expenses incurred before the date of the [October 25,
2016] hearing.” 2016 C&R Agreement, ¶10; R.R. 59a. The Addendum to Paragraph
10 purports to exclude Pharmacy’s 2016 invoice from its reach for the stated reason
that Dr. Bundy has a financial interest in Pharmacy. However, there is no evidence
that Dr. Bundy has a financial interest in Pharmacy, and there has not been a legal
determination that this financial relationship, if it exists, violates the Act. The stated
“belief” of the parties in the 2016 C&R Agreement on this legal question is
meaningless.
             The 2016 C&R Agreement requires Employer to pay for all reasonable
and necessary medical expenses incurred prior to hearing, and it is for the utilization
review organization to decide whether the compound cream treatment was
reasonable and necessary. It did so in 2015, and Employer never challenged that
determination. A C&R Agreement cannot be employed to avoid the procedures in
the Act for challenging a provider’s invoice or a fee review determination that the
invoice must be paid. To hold otherwise would eviscerate Section 301(f.1)(5) and
(6) of the Act and violate the due process of law guaranteed to providers.
             Accordingly, we vacate the adjudication of the Hearing Office that the
2016 C&R Agreement eliminated Employer’s liability to Pharmacy. We remand to
the Bureau for a decision on the merits of Employer’s request for a hearing to contest
the fee review determination of July 25, 2016, in favor of Pharmacy.
                                     ______________________________________
                                     MARY HANNAH LEAVITT, President Judge

                                           14
             IN THE COMMONWEALTH COURT OF PENNSYLVANIA

Armour Pharmacy,                         :
                   Petitioner            :
                                         :
            v.                           : No. 1613 C.D. 2017
                                         :
Bureau of Workers’ Compensation          :
Fee Review Hearing Office (National      :
Fire Insurance Company of Hartford),     :
                  Respondent             :

                                    ORDER

            AND NOW, this 7th day of August, 2018, the order of the Bureau of
Workers’ Compensation, Fee Review Hearing Office of October 3, 2017, is
VACATED and the matter is REMANDED for a decision on the merits of the
request for a hearing to contest the fee review determination filed by National Fire
Insurance Company of Hartford, in accordance with the attached opinion.
            Jurisdiction relinquished.
                                   ______________________________________
                                   MARY HANNAH LEAVITT, President Judge